Checkmate Pharmaceuticals, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$61.5M | −$36.9M | −$28.9M |
| Net income | −$61.4M | −$36.9M | −$28.3M |
| Total assets | $78.8M | $133.1M | $5.1M |
| Total liabilities | $9.4M | $7.9M | $5.6M |
| Equity | $69.5M | $125.2M | −$97.4M |
| EPS (diluted) | — | — | — |
| Shares out. | 21.6M | 21.6M | 1.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −88.4%
- Return on assets
- −77.9%
- Return on capital (ROCE)
- −88.5%
- Liabilities / assets
- 11.9%
- Debt / equity
- 0.14×
- Book value / share
- $3.21
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -0.42distress
- Accruals / assets
- −9.8%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 31, 2022
- Results of operationsMay 12, 2022
- Entered a material agreementApr 19, 2022
- Other material eventApr 19, 2022
- Results of operationsMar 30, 2022
- Director / officer changeMar 1, 2022
- Director / officer changeFeb 9, 2022
- Director / officer changeFeb 1, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BJun 10, 2022
- SC 13G/AJun 7, 2022
- SC 13D/ASCHEDULE 13D - AMENDMENT NO. 1Jun 7, 2022
- SC 13D/AJun 3, 2022
- SC 13DSCHEDULE 13D - CHECKMATE PHARMACEUTICALS, INC.Jun 3, 2022
- EFFECTJun 1, 2022
- 25-NSEMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
- 4FORM 4 SUBMISSIONMay 31, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.